Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00672061 · ClinicalTrials.gov registry record · Phase 2

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

A Phase 2 study of Sleep Apnea, Obstructive, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target
5
Study locations

NCT00672061 is a Phase 2 study of Sleep Apnea, Obstructive that has completed, run by Takeda. The registered enrollment target is 26 participants, below the 262-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00672061, a Phase 2 study of Sleep Apnea, Obstructive, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.

Conditions Studied

Interventions

  • DRUG Ramelteon or Placebo

Study Locations (5)

California

  • - Palm Springs
  • - Santa Monica

Alabama

  • - Birmingham

Florida

  • - Winter Park

Ohio

  • - Cincinnati

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2003-07
Est. Completion 2003-12
Phase Phase 2

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT00672061

The ClinicalTrials.gov registry entry for NCT00672061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (90% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sleep Apnea, Obstructive appearing as the primary indexed condition, and to 1 intervention - of which Ramelteon or Placebo is the first listed.

NCT00672061 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT00672061 about?

NCT00672061 is a clinical study titled "Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea". The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.

What is the current status of trial NCT00672061?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-07. Estimated completion is 2003-12.

What conditions does trial NCT00672061 study?

This clinical trial studies the following conditions: Sleep Apnea, Obstructive.

What interventions are being tested in trial NCT00672061?

The interventions under investigation include: Ramelteon or Placebo (DRUG).

Who is sponsoring clinical trial NCT00672061?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00672061 being conducted?

This trial has 5 study locations across Alabama, California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Apnea, Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.